Table 5.
Clearance Rates by pfcrt mutation at baseline in study A00661120 (India)
| AZCQ 1 g (n = 83)
|
AZCQ 500 mg (n = 67)
|
SPCQ (n = 80)
|
||||
|---|---|---|---|---|---|---|
| n/N | % of total | n/N | % of total | n/N | % of total | |
| CVMNK sensitive | 5/5 (100%) | 6.0 | 6/6 (100%) | 9.0 | 7/7 (100%) | 8.8 |
| CQ resistant | 64/75 (85.3%) | 77.1 | 41/59 (69.5%) | 61.2 | 63/69 (91.3%) | 78.8 |
| SVMNT | 54/64 (84.4%) | 65.1 | 33/49 (67.3%) | 49.3 | 51/56 (91.1%) | 63.8 |
| CVIET | 10/11 (90.9%) | 12.0 | 8/10 (80.0%) | 11.9 | 12/13 (92.3%) | 15.0 |
| Negative | 2/2 (100%) | 2.4 | 1/1 (100%) | 1.5 | 1/2 (50%) | 1.3 |
| Othersa | 1/1 (100%) | 1.2 | 0/1 (0%) | 0.0 | 2/2 (100%) | 2.5 |
Notes: n, number of subjects cleared at Day 28; N, number of subjects with the respective mutations at baseline; CVIET, Southeast Asian/African origin; CVMNK, wild type; SVMNT, South American origin.
a
Others included P. vivax or missing sample.
Abbreviations: AZCQ, azithromycin–chloroquine; CQ, chloroquine; P. vivax, Plasmodium vivax; SPCQ, chloroquine plus sulfadoxine–pyrimethamine.